Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
08
2019
revised:
01
01
2020
accepted:
10
01
2020
pubmed:
28
2
2020
medline:
2
7
2020
entrez:
28
2
2020
Statut:
ppublish
Résumé
The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) has been used around the world to assess the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls. We updated PRIME with new data and methods for demography, disability weights, and cervical cancer burden, and generated revised estimates of the health impact of HPV vaccination at the global, regional, and national levels for 177 countries. PRIME was updated with population demography of the UN World Population Prospects (UNWPP) 2019 revision, disability weights of the Global Burden of Disease (GBD) 2017 study, and cervical cancer burden from the Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018 database. We estimated the lifetime health benefits for bivalent or quadrivalent and nonavalent vaccination of 9-year-old and 12-year-old girls at 90% coverage during 2020-29 in 177 countries. Health impact was presented in terms of cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000 vaccinated girls in comparison with the counterfactual scenario of no vaccination, and the number of girls needed to be vaccinated to prevent a single case, death, or DALY. In estimating the health impact of HPV vaccination of 9-year-old girls, the combined updates to demography, disability weights, cervical cancer burden estimates resulted in a 26% increase in the estimated number of cases averted, a 51% increase in deaths averted, and a 72% increase in DALYs averted per 1000 vaccinated girls for both the bivalent or quadrivalent and nonavalent vaccines, compared with previous estimates. With the updated model, the bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases, 12 deaths, and 243 DALYs per 1000 vaccinated girls, and the nonavalent HPV vaccine was estimated to avert 19 cases, 14 deaths, and 306 DALYs per 1000 vaccinated girls. The health benefits of vaccination of 12-year-old girls were estimated to be similar but slightly decreased in comparison with vaccination of 9-year-old girls. HPV vaccination provides greater health benefits and is more cost-effective than was previously estimated. The demography update, which incorporates population aging, has the largest effect on the health impact estimates. The WHO African region is expected to gain the greatest health benefits and should be prioritised for HPV vaccination. Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Sections du résumé
BACKGROUND
The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) has been used around the world to assess the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls. We updated PRIME with new data and methods for demography, disability weights, and cervical cancer burden, and generated revised estimates of the health impact of HPV vaccination at the global, regional, and national levels for 177 countries.
METHODS
PRIME was updated with population demography of the UN World Population Prospects (UNWPP) 2019 revision, disability weights of the Global Burden of Disease (GBD) 2017 study, and cervical cancer burden from the Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018 database. We estimated the lifetime health benefits for bivalent or quadrivalent and nonavalent vaccination of 9-year-old and 12-year-old girls at 90% coverage during 2020-29 in 177 countries. Health impact was presented in terms of cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000 vaccinated girls in comparison with the counterfactual scenario of no vaccination, and the number of girls needed to be vaccinated to prevent a single case, death, or DALY.
FINDINGS
In estimating the health impact of HPV vaccination of 9-year-old girls, the combined updates to demography, disability weights, cervical cancer burden estimates resulted in a 26% increase in the estimated number of cases averted, a 51% increase in deaths averted, and a 72% increase in DALYs averted per 1000 vaccinated girls for both the bivalent or quadrivalent and nonavalent vaccines, compared with previous estimates. With the updated model, the bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases, 12 deaths, and 243 DALYs per 1000 vaccinated girls, and the nonavalent HPV vaccine was estimated to avert 19 cases, 14 deaths, and 306 DALYs per 1000 vaccinated girls. The health benefits of vaccination of 12-year-old girls were estimated to be similar but slightly decreased in comparison with vaccination of 9-year-old girls.
INTERPRETATION
HPV vaccination provides greater health benefits and is more cost-effective than was previously estimated. The demography update, which incorporates population aging, has the largest effect on the health impact estimates. The WHO African region is expected to gain the greatest health benefits and should be prioritised for HPV vaccination.
FUNDING
Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Identifiants
pubmed: 32105613
pii: S2214-109X(20)30022-X
doi: 10.1016/S2214-109X(20)30022-X
pmc: PMC7083230
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e536-e544Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Infect Agent Cancer. 2012 Dec 29;7(1):38
pubmed: 23273245
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Value Health. 2018 Oct;21(10):1250-1258
pubmed: 30314627
Lancet Public Health. 2016 Nov;1(1):e8-e17
pubmed: 29253379
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Emerg Infect Dis. 2016 Jan;22(1):18-23
pubmed: 26691673
Vaccine. 2008 Jul 29;26(32):4080-93
pubmed: 18550229
Int J Cancer. 2011 Feb 15;128(4):927-35
pubmed: 20473886
Cost Eff Resour Alloc. 2014 Aug 29;12:18
pubmed: 25246855
Lancet. 2018 Sep 22;392(10152):985
pubmed: 30264708
Wkly Epidemiol Rec. ;92(19):241-68
pubmed: 28530369
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
J Glob Oncol. 2017 Mar 17;3(5):611-634
pubmed: 29094100
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Lancet Glob Health. 2014 Jul;2(7):e406-14
pubmed: 25103394
BMC Health Serv Res. 2017 May 15;17(1):353
pubmed: 28506297
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Int J Cancer. 2018 Jul 15;143(2):317-323
pubmed: 29446090
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593